

# Ezequiel Ruiz-Mateos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/836346/publications.pdf>

Version: 2024-02-01

122  
papers

3,056  
citations

172457

29  
h-index

206112

48  
g-index

127  
all docs

127  
docs citations

127  
times ranked

4214  
citing authors

#	ARTICLE	IF	CITATIONS
1	In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. <i>Journal of Cell Biology</i> , 2007, 177, 329-341.	5.2	292
2	Follicular CD8 T cells accumulate in HIV infection and can kill infected cells in vitro via bispecific antibodies. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	135
3	Inositol pyrophosphate mediated pyrophosphorylation of AP3B1 regulates HIV-1 Gag release. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 21161-21166.	7.1	127
4	Thymic function failure and C-reactive protein levels are independent predictors of all-cause mortality in healthy elderly humans. <i>Age</i> , 2013, 35, 251-259.	3.0	95
5	Age-related deregulation of naive T cell homeostasis in elderly humans. <i>Age</i> , 2011, 33, 197-207.	3.0	89
6	Dendritic cell deficiencies persist seven months after SARS-CoV-2 infection. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2128-2139.	10.5	81
7	Long-Term Suppressive Combined Antiretroviral Treatment Does Not Normalize the Serum Level of Soluble CD14. <i>Journal of Infectious Diseases</i> , 2013, 207, 1221-1225.	4.0	69
8	Rate and predictors of progression in elite and viremic HIV-1 controllers. <i>Aids</i> , 2016, 30, 1209-1220.	2.2	69
9	Plasmacytoid Dendritic Cells Reduce HIV Production in Elite Controllers. <i>Journal of Virology</i> , 2012, 86, 4245-4252.	3.4	66
10	Plasmacytoid Dendritic Cells (pDCs) From HIV Controllers Produce Interferon- $\beta$ and Differentiate Into Functional Killer pDCs Under HIV Activation. <i>Journal of Infectious Diseases</i> , 2012, 206, 790-801.	4.0	62
11	Sensitive Deep-Sequencing-Based HIV-1 Genotyping Assay To Simultaneously Determine Susceptibility to Protease, Reverse Transcriptase, Integrase, and Maturation Inhibitors, as Well as HIV-1 Coreceptor Tropism. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 2167-2185.	3.2	61
12	Hepatitis C Therapy With Interferon- $\beta$ and Ribavirin Reduces CD4 T-Cell-Associated HIV-1 DNA in HIV-1/Hepatitis C Virus-Coinfected Patients. <i>Journal of Infectious Diseases</i> , 2014, 209, 1315-1320.	4.0	60
13	Factors Leading to the Loss of Natural Elite Control of HIV-1 Infection. <i>Journal of Virology</i> , 2018, 92, .	3.4	58
14	Immunometabolism is a key factor for the persistent spontaneous elite control of HIV-1 infection. <i>EBioMedicine</i> , 2019, 42, 86-96.	6.1	55
15	A reliable and simplified sj $\beta$ 2-TREC ratio quantification method for human thymic output measurement. <i>Journal of Immunological Methods</i> , 2010, 352, 111-117.	1.4	54
16	Differential Gag-Specific Polyfunctional T Cell Maturation Patterns in HIV-1 Elite Controllers. <i>Journal of Virology</i> , 2012, 86, 3667-3674.	3.4	52
17	Signatures of immune selection in intact and defective proviruses distinguish HIV-1 elite controllers. <i>Science Translational Medicine</i> , 2021, 13, eabl4097.	12.4	52
18	Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure. <i>Scientific Reports</i> , 2020, 10, 1902.	3.3	50

#	ARTICLE	IF	CITATIONS
19	CD63 Is Not Required for Production of Infectious Human Immunodeficiency Virus Type 1 in Human Macrophages. <i>Journal of Virology</i> , 2008, 82, 4751-4761.	3.4	46
20	TNF- $\alpha$ levels in HIV-infected patients after long-term suppressive cART persist as high as in elderly, HIV-uninfected subjects. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 3041-3046.	3.0	46
21	Thymic volume is associated independently with the magnitude of short- and long-term repopulation of CD4+ T cells in HIV-infected adults after highly active antiretroviral therapy (HAART)1. <i>Clinical and Experimental Immunology</i> , 2004, 136, 501-506.	2.6	41
22	Different biological significance of sCD14 and LPS in HIV-infection: Importance of the immunovirology stage and association with HIV-disease progression markers. <i>Journal of Infection</i> , 2012, 65, 431-438.	3.3	41
23	Endogenous IL-7 is associated with increased thymic volume in adult HIV-infected patients under highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 947-954.	2.2	36
24	A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2493-2501.	3.0	35
25	Analysis of Non-AIDS-Defining Events in HIV Controllers. <i>Clinical Infectious Diseases</i> , 2016, 62, 1304-1309.	5.8	34
26	HIV Infection-Related Premature Immunosenescence: High Rates of Immune Exhaustion After Short Time of Infection. <i>Current HIV Research</i> , 2011, 9, 289-294.	0.5	33
27	Monocyte Phenotype and Polyfunctionality Are Associated With Elevated Soluble Inflammatory Markers, Cytomegalovirus Infection, and Functional and Cognitive Decline in Elderly Adults. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2016, 71, 610-618.	3.6	33
28	Thymic Function Failure Is Associated With Human Immunodeficiency Virus Disease Progression. <i>Clinical Infectious Diseases</i> , 2017, 64, 1191-1197.	5.8	30
29	Pegylated Interferon- $\alpha$ Induced Natural Killer Cell Activation Is Associated With Human Immunodeficiency Virus-1 DNA Decline in Antiretroviral Therapy-Treated HIV-1/Hepatitis C Virus-Coinfected Patients. <i>Clinical Infectious Diseases</i> , 2018, 66, 1910-1917.	5.8	30
30	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. <i>PLoS ONE</i> , 2017, 12, e0173893.	2.5	30
31	Different profiles of immune reconstitution in children and adults with HIV-infection after highly active antiretroviral therapy. <i>BMC Infectious Diseases</i> , 2006, 6, 112.	2.9	29
32	Hepatitis C virus replication in Caucasian HIV controllers. <i>Journal of Viral Hepatitis</i> , 2011, 18, e350-7.	2.0	29
33	Differential alterations of the CD4 and CD8 T cell subsets in HIV-infected patients on highly active antiretroviral therapy with low CD4 T cell restoration. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 1228-1237.	3.0	29
34	Correlation between the Trofile(R) test and virological response to a short-term maraviroc exposure in HIV-infected patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2009, 64, 845-849.	3.0	28
35	CD4 T-cell regeneration in HIV-1 elite controllers. <i>Aids</i> , 2012, 26, 701-706.	2.2	28
36	HLA-B*57 and IFNL4-related polymorphisms are associated with protection against HIV-1 disease progression in controllers. <i>Clinical Infectious Diseases</i> , 2017, 64, ciw833.	5.8	28

#	ARTICLE	IF	CITATIONS
37	Thymic Function Impacts the Peripheral CD4/CD8 Ratio of HIV-Infected Subjects. <i>Clinical Infectious Diseases</i> , 2017, 64, 152-158.	5.8	26
38	Immunological history governs human stem cell memory CD4 heterogeneity via the Wnt signaling pathway. <i>Nature Communications</i> , 2020, 11, 821.	12.8	25
39	Changes in thymus volume in adult HIV-infected patients under HAART: correlation with the T-cell repopulation. <i>Clinical and Experimental Immunology</i> , 2002, 130, 121-126.	2.6	24
40	PLA2G1B is involved in CD4 anergy and CD4 lymphopenia in HIV-infected patients. <i>Journal of Clinical Investigation</i> , 2020, 130, 2872-2887.	8.2	24
41	Specific patterns of CD4-associated immunosenescence in vertically HIV-infected subjects. <i>Clinical Microbiology and Infection</i> , 2013, 19, 558-565.	6.0	23
42	Maraviroc Reduces the Regulatory T-Cell Frequency in Antiretroviral-Naive HIV-Infected Subjects. <i>Journal of Infectious Diseases</i> , 2014, 210, 890-898.	4.0	23
43	WNT Signaling Suppression in the Senescent Human Thymus. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 273-281.	3.6	23
44	Proteomic Profile Associated With Loss of Spontaneous Human Immunodeficiency Virus Type 1 Elite Control. <i>Journal of Infectious Diseases</i> , 2019, 219, 867-876.	4.0	23
45	Evidence of Thymic Function in Heavily Antiretroviral-Treated Human Immunodeficiency Virus Type 1-Infected Adults with Long-Term Virologic Treatment Failure. <i>Journal of Infectious Diseases</i> , 2002, 186, 410-414.	4.0	22
46	IL28B Single-Nucleotide Polymorphism rs12979860 Is Associated With Spontaneous HIV Control in White Subjects. <i>Journal of Infectious Diseases</i> , 2013, 207, 651-655.	4.0	22
47	Long-term virological outcome and resistance mutations at virological rebound in HIV-infected adults on protease inhibitor-sparing highly active antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2003, 53, 95-101.	3.0	21
48	TROCAI (Tropism Coreceptor Assay Information): a New Phenotypic Tropism Test and Its Correlation with Trofile Enhanced Sensitivity and Genotypic Approaches. <i>Journal of Clinical Microbiology</i> , 2010, 48, 4453-4458.	3.9	21
49	Prevalence of Transmitted HIV-1 Drug Resistance Mutations in Children and Adolescents in São Paulo, Brazil. <i>Pediatric Infectious Disease Journal</i> , 2012, 31, e255-e257.	2.0	21
50	Detectable Viral Load Aggravates Immunosenescence Features of CD8 T-Cell Subsets in Vertically HIV-Infected Children. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 60, 447-454.	2.1	20
51	CD27 and CCR7 expression on naive T cells, are both necessary?. <i>Immunology Letters</i> , 2010, 127, 157-158.	2.5	19
52	Correlation of the Virological Response to Short-Term Maraviroc Monotherapy with Standard and Deep-Sequencing-Based Genotypic Tropism Prediction Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1202-1207.	3.2	19
53	Effect of Maraviroc on HIV Disease Progression-Related Biomarkers. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 5858-5864.	3.2	19
54	Class-modeling analysis reveals T-cell homeostasis disturbances involved in loss of immune control in elite controllers. <i>BMC Medicine</i> , 2018, 16, 30.	5.5	19

#	ARTICLE	IF	CITATIONS
55	IFNL4 ss469415590 polymorphism is associated with unfavourable clinical and immunological status in HIV-infected individuals. <i>Clinical Microbiology and Infection</i> , 2015, 21, 289.e1-289.e4.	6.0	18
56	Long-Term Immunovirological Effect and Tolerability of a Maraviroc- Containing Regimen in Routine Clinical Practice. <i>Current HIV Research</i> , 2010, 8, 482-486.	0.5	17
57	A Lower Baseline CD4/CD8 T-Cell Ratio Is Independently Associated with Immunodiscordant Response to Antiretroviral Therapy in HIV-Infected Subjects. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
58	Baseline Thymic Volume is a Predictor for CD4 T Cell Repopulation in Adult HIV-Infected Patients under Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2002, 7, 159-163.	1.0	17
59	Immunity in HIV-1-Infected Adults with a Previous State of Moderate-Severe Immune-Suppression and More Than 500 CD4+ T Cell After Highly Active Antiretroviral Therapy. <i>Journal of Clinical Immunology</i> , 2004, 24, 379-388.	3.8	16
60	Thymic Function-Related Markers Within the Thymus and Peripheral Blood: Are They Comparable?. <i>Journal of Clinical Immunology</i> , 2006, 26, 96-100.	3.8	16
61	Toll-Like Receptor 7 (TLR-7) and TLR-9 Agonists Improve Hepatitis C Virus Replication and Infectivity Inhibition by Plasmacytoid Dendritic Cells. <i>Journal of Virology</i> , 2018, 92, .	3.4	16
62	Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapy. <i>Atherosclerosis</i> , 2018, 273, 28-36.	0.8	15
63	Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearanceâ€”Supercontrollers. <i>Frontiers in Immunology</i> , 2018, 9, 2897.	4.8	15
64	High Levels of CD57+CD28- T-Cells, Low T-Cell Proliferation and Preferential Expansion of Terminally Differentiated CD4+ T-Cells in HIVelite Controllers. <i>Current HIV Research</i> , 2010, 8, 471-481.	0.5	15
65	Maintenance of virologic efficacy and decrease in levels of Î²2-microglobulin, soluble CD40L and soluble CD14 after switching previously treated HIV-infected patients to an NRTI-sparing dual therapy. <i>Antiviral Research</i> , 2014, 111, 26-32.	4.1	14
66	Phenotype and Polyfunctional Deregulation Involving Interleukin 6 (IL-6)â€” and IL-10â€”Producing Monocytes in HIV-Infected Patients Receiving Combination Antiretroviral Therapy Differ From Those in Healthy Older Individuals. <i>Journal of Infectious Diseases</i> , 2016, 213, 999-1007.	4.0	14
67	Elevated Anti-SARS-CoV-2 Antibodies and IL-6, IL-8, MIP-1Î², Early Predictors of Severe COVID-19. <i>Microorganisms</i> , 2021, 9, 2259.	3.6	14
68	Massive Release of CD9+ Microvesicles in Human Immunodeficiency Virus Infection, Regardless of Virologic Control. <i>Journal of Infectious Diseases</i> , 2022, 225, 1040-1049.	4.0	13
69	Comparison of Thymic Function-Related Markers to Predict Early Cd4 T-Cell Repopulation in Adult HIV-Infected Patients on Haart. <i>Antiviral Therapy</i> , 2003, 8, 289-294.	1.0	13
70	High Thymic Volume Is Associated With Viral Replication and Immunologic Impairment Only Early After HAART Interruption in Chronic HIV Infection. <i>Viral Immunology</i> , 2005, 18, 740-746.	1.3	11
71	Virological Response after Short-Term CCR5 Antagonist Exposure in HIV-Infected Patients: Frequency of Subjects with Virological Response and Associated Factors. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 4664-4669.	3.2	11
72	IFNÎ³<sup>âˆ—</sup></sup>TNFÎ±<sup>âˆ—</sup></sup>IL2<sup>âˆ—</sup></sup>MIP1Î±<sup>âˆ—</sup></sup>CD107a<sup>+</sup></sup>PRF1<sup>+</sup></sup>CD8 pp65-Specific T-Cell Response Is Independently Associated With Time to Death in Elderly Humans. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2015, 70, 1210-1218.	3.6	11

#	ARTICLE	IF	CITATIONS
73	Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers. <i>Frontiers in Immunology</i> , 2018, 9, 1709.	4.8	11
74	Antiretroviral Treatment for HIV Elite Controllers?. <i>Pathogens and Immunity</i> , 2020, 5, 121.	3.1	11
75	SARS-CoV-2 Evolution and Spike-Specific CD4+ T-Cell Response in Persistent COVID-19 with Severe HIV Immune Suppression. <i>Microorganisms</i> , 2022, 10, 143.	3.6	11
76	FetuinA, interleukin-6, trypsin inhibitor, glutamic acid and ChoE (18:0) are key biomarkers in a panel distinguishing mild from critical coronavirus disease 2019 outcomes. <i>Clinical and Translational Medicine</i> , 2022, 12, e704.	4.0	11
77	Effect of Hepatitis C Virus Coinfection on Humoral Immune Alterations in Naïve HIV-Infected Adults on HAART: A Three Year Follow-Up Study. <i>Journal of Clinical Immunology</i> , 2005, 25, 296-302.	3.8	10
78	Discordance rates between Trofile® test and short-term virological response to maraviroc. <i>Antiviral Research</i> , 2011, 89, 182-185.	4.1	10
79	Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naïve HIV-infected subjects. <i>Clinical Microbiology and Infection</i> , 2016, 22, 461.e1-461.e5.	6.0	10
80	Immunovirologic Characteristics of Human Immunodeficiency Virus-Infected Patients Consisting Mainly of Injecting Drug Users on Highly Active Antiretroviral Treatment with Prolonged Virologic Failure. <i>Viral Immunology</i> , 2006, 19, 759-767.	1.3	9
81	T-cell changes after a short-term exposure to maraviroc in HIV-infected patients are related to antiviral activity. <i>Journal of Infection</i> , 2012, 64, 417-423.	3.3	9
82	CCR5+ CD8 T-cell levels and monocyte activation precede the onset of acute coronary syndrome in HIV-infected patients on antiretroviral therapy. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1141-1149.	3.4	9
83	Prevalence of HIV-1 Dual Infection in Long-Term Nonprogressor "Elite Controllers. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2013, 64, 225-231.	2.1	8
84	Mesenchymal stromal cells in human immunodeficiency virus-infected patients with discordant immune response: Early results of a phase I/II clinical trial. <i>Stem Cells Translational Medicine</i> , 2021, 10, 534-541.	3.3	8
85	Deciphering the quality of SARS-CoV-2 specific T cell response associated with disease severity, immune memory and heterologous response. <i>Clinical and Translational Medicine</i> , 2022, 12, e802.	4.0	8
86	HIV-1 Tropism Evolution after Short-Term Maraviroc Monotherapy in HIV-1-Infected Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 3981-3983.	3.2	7
87	Immunovirological Efficacy of Once-Daily Maraviroc Plus Ritonavir-Boosted Atazanavir After 48 Weeks in Naïve HIV-Infected Patients. <i>Viral Immunology</i> , 2016, 29, 471-477.	1.3	7
88	The Other Side of SARS-CoV-2 Infection: Neurological Sequelae in Patients. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 632673.	3.4	7
89	Patients on a combined antiretroviral therapy after maraviroc clinical test show no immunovirological impairment. <i>Antiviral Research</i> , 2012, 95, 207-211.	4.1	6
90	Efficacy and tolerability after 24weeks of treatment with telaprevir, pegylated interferon and ribavirin in cirrhotic HIV-HCV coinfecting subjects. <i>Antiviral Research</i> , 2014, 104, 59-61.	4.1	6

#	ARTICLE	IF	CITATIONS
91	Increased CD127+ and decreased CD57+ T cell expression levels in HIV-infected patients on NRTI-sparing regimens. <i>Journal of Translational Medicine</i> , 2017, 15, 259.	4.4	6
92	Association of heterozygous CCR5 $\Delta$ 32 deletion with survival in HIV-infection: A cohort study. <i>Antiviral Research</i> , 2018, 150, 15-19.	4.1	6
93	High CD8 T cell percentage and HCV replication control are common features in HIV-1 controllers and HTLV-2-co-infected patients with a history of injection drug use. <i>Virus Research</i> , 2019, 264, 40-44.	2.2	6
94	Development of Immature CD4+CD8+T Cells Into Mature CD4+ T Cells Requires Alpha-1 Antitrypsin as Observed by Treatment in HIV-1 Infected and Uninfected Controls. <i>Frontiers in Cell and Developmental Biology</i> , 2019, 7, 278.	3.7	6
95	Disseminate and fatal cytomegalovirus disease with thymitis in a naive HIV-patient after early initiation of HAART: Immune restoration disease?. <i>Journal of Clinical Virology</i> , 2006, 36, 13-16.	3.1	5
96	Maraviroc Clinical Test (MCT) as an alternative tool to decide CCR5-antagonists prescription in naïve HIV-infected patients. <i>Antiviral Research</i> , 2015, 121, 94-96.	4.1	5
97	Relationship between CCR5(WT/ $\Delta$ 32) heterozygosity and HIV-1 reservoir size in adolescents and young adults with perinatally acquired HIV-1 infection. <i>Clinical Microbiology and Infection</i> , 2017, 23, 318-324.	6.0	5
98	Long-term Persistent Elite HIV-controllers: The Right Model of Functional Cure. <i>EBioMedicine</i> , 2018, 28, 15-16.	6.1	5
99	Improved CD4 T cell profile in HIV-infected subjects on maraviroc-containing therapy is associated with better responsiveness to HBV vaccination. <i>Journal of Translational Medicine</i> , 2018, 16, 238.	4.4	5
100	Comparison of thymic function-related markers to predict early CD4 T-cell repopulation in adult HIV-infected patients on HAART. <i>Antiviral Therapy</i> , 2003, 8, 289-94.	1.0	5
101	Simplified sequence-specific oligonucleotide-based polymerase chain reaction protocol to characterize human major histocompatibility complex A*02 and A*24 specificities. <i>Human Immunology</i> , 2011, 72, 869-871.	2.4	4
102	Association between a Suppressive Combined Antiretroviral Therapy Containing Maraviroc and the Hepatitis B Virus Vaccine Response. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	4
103	Is immune recovery different depending on the use of integrase strand transfer inhibitor-, non-nucleoside reverse transcriptase- or boosted protease inhibitor-based regimens in antiretroviral-naive HIV-infected patients?. <i>Journal of Antimicrobial Chemotherapy</i> , 2020, 75, 200-207.	3.0	4
104	IL-7/IL-7R gene variants impact circulating IL-7/IL-7R homeostasis and ART-associated immune recovery status. <i>Scientific Reports</i> , 2019, 9, 15722.	3.3	4
105	Hepatitis C virus and cumulative infections are associated with atherogenic cardiovascular events in HIV-infected subjects. <i>Antiviral Research</i> , 2019, 169, 104527.	4.1	4
106	Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a. <i>Scientific Reports</i> , 2020, 10, 6070.	3.3	4
107	Elevated $\alpha$ -Ketoglutaric Acid Concentrations and a Lipid-Balanced Signature Are the Key Factors in Long-Term HIV Control. <i>Frontiers in Immunology</i> , 2022, 13, 822272.	4.8	4
108	Role of toll-like receptor 4 Asp299Gly polymorphism in the development of cardiovascular diseases in HIV-infected patients. <i>Aids</i> , 2018, 32, 1035-1041.	2.2	3

#	ARTICLE	IF	CITATIONS
109	Modulation of Monocyte Activation and Function during Direct Antiviral Agent Treatment in Patients Coinfected with HIV and Hepatitis C Virus. <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	3
110	Differential miRNA plasma profiles associated with the spontaneous loss of HIV-1 control: miR-199a-3p and its potential role as a biomarker for quick screening of elite controllers. <i>Clinical and Translational Medicine</i> , 2021, 11, e474.	4.0	3
111	Immunescape of HIV-1 in Env-EL9 CD8 <sup>+</sup> T cell response restricted by HLA-B*14:02 in a Non progressor who lost twenty-seven years of HIV-1 control. <i>Retrovirology</i> , 2022, 19, 6.	2.0	3
112	Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients. <i>Drug Design, Development and Therapy</i> , 2016, 10, 353.	4.3	2
113	Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients. <i>International Journal of Medical Sciences</i> , 2018, 15, 95-100.	2.5	2
114	CD300a identifies a CD4 <sup>+</sup> memory T cell subset with a higher susceptibility to HIV-1 infection. <i>Aids</i> , 2020, 34, 1249-1252.	2.2	2
115	Persistent HIV-1 controllers are more prone to spontaneously clear HCV: a retrospective cohort study. <i>Journal of the International AIDS Society</i> , 2020, 23, e25607.	3.0	2
116	Evolution of Serum Acute-Phase Glycoproteins Assessed by 1H-NMR in HIV Elite Controllers. <i>Frontiers in Immunology</i> , 2021, 12, 730691.	4.8	2
117	Past and future of HIV infection. A document based on expert opinion. <i>Revista Espanola De Quimioterapia</i> , 2022, 35, 131-156.	1.3	2
118	Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 6398-6401.	3.2	0
119	Reply to Kuniholm et al. <i>Clinical Infectious Diseases</i> , 2017, 65, 1244-1245.	5.8	0
120	Specific Patterns of T Cell Immunosenescence in Vertically HIV-Infected Subjects. , 2018, , 1-18.		0
121	In macrophages, HIV-1 assembles into an intracellular plasma membrane domain containing the tetraspanins CD81, CD9, and CD53. <i>Journal of Experimental Medicine</i> , 2007, 204, i13-i13.	8.5	0
122	Specific Patterns of T Cell Immunosenescence in Vertically HIV-Infected Subjects. , 2019, , 1865-1882.		0